High Evidence
Research Overview
Liraglutide Research for Cardiovascular Disease
An evidence-based overview of research examining Liraglutide in the context of cardiovascular disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
LEADER trial demonstrated 13% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) and 22% reduction in cardiovascular death in T2D patients with high CV risk. FDA label includes indication for CV risk reduction.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Cardiovascular Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Liraglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.